We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| (MM) | NASDAQ:MBLTY | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0 | - |
From Jul 2019 to Jul 2024
By Robb M. Stewart
MELBOURNE, Australia--U.S. biopharmaceutical company Celgene Corp. (CELG) agreed to buy a stake in Australian regenerative-medicine specialist Mesoblast Ltd. (MSB.AU) in a deal that also secures potential access to prospective treatments in a range of disease fields.
Celgene will buy 15.3 million shares in Mesoblast for 58.5 million Australian dollars (US$44.9 million), equal to A$3.82 a share, Mesoblast said Monday.
Celgene also will have a six-month right of first refusal to Mesoblast's mesenchymal lineage adult-stem-cell product candidates for the prevention and treatment of acute graft versus host disease, certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection.
Celgene, which focuses on the development of therapies for the treatment of cancer and immune-inflammatory related diseases, said the deal will bolster its pipeline of cellular and regenerative medicines.
Write to Robb M. Stewart at robb.stewart@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year (MM) Chart |
1 Month (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
